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Abstract
Leber’s hereditary optic neuropathy (LHON) is characterized by retinal ganglion cell (RGC) degeneration with the
preferential involvement of those forming the papillomacular bundle. The optic nerve is considered the main pathological
target for LHON. Our aim was to investigate the possible involvement of the post-geniculate visual pathway in LHON
patients. We used diffusion-weighted imaging for in vivo evaluation. Mean diffusivity maps from 22 LHON visually impaired,
11 unaffected LHON mutation carriers and 22 healthy subjects were generated and compared at level of optic radiation
(OR). Prefrontal and cerebellar white matter were also analyzed as internal controls. Furthermore, we studied the optic nerve
and the lateral geniculate nucleus (LGN) in post-mortem specimens obtained from a severe case of LHON compared to an
age-matched control. Mean diffusivity values of affected patients were higher than unaffected mutation carriers (P,0.05)
and healthy subjects (P,0.01) in OR and not in the other brain regions. Increased OR diffusivity was associated with both
disease duration (B = 0.002; P,0.05) and lack of recovery of visual acuity (B = 0.060; P,0.01). Post-mortem investigation
detected atrophy (41.9% decrease of neuron soma size in the magnocellular layers and 44.7% decrease in the parvocellular
layers) and, to a lesser extent, degeneration (28.5% decrease of neuron density in the magnocellular layers and 28.7%
decrease in the parvocellular layers) in the LHON LGN associated with extremely severe axonal loss (99%) in the optic nerve.
The post-geniculate involvement in LHON patients is a downstream post-synaptic secondary phenomenon, reflecting de-
afferentation rather than a primary neurodegeneration due to mitochondrial dysfunction of LGN neurons.
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Introduction
Leber’s hereditary optic neuropathy (LHON) is a mitochondrial
disease characterized by retinal ganglion cells (RGCs) degenera-
tion due to maternally inherited point mutations in mitochondrial
DNA (mtDNA) that affect the respiratory complex I [1,2].
Characteristically, the degenerative process preferentially involves
the RGCs forming the papillomacular bundle serving central
vision, colour vision and high spatial frequency contrast sensitivity
[3]. LHON affects prevalently young males, who suffer an acute/
subacute loss of central vision that leads to rapid decrease of visual
acuity due to central scotoma. This acute phase consolidates in
a chronic state in about one year after the onset of visual loss,
leaving the patients with optic atrophy and usually permanent
blindness [1,2].
However, some of the patients may experience various degrees
of visual function recovery, with gain of visual acuity and
shrinkage or fenestration of the central scotoma at visual field
[1,2]. This recovery may occur spontaneously, most frequently
with one of the common mutations at position 14484/ND6 and if
the age at disease onset is precocious, irrespectively the mutation
type. Recently, it has been demonstrated that administration of
idebenone may also increase the rate of visual function recovery
[4,5]. Long-lasting chronic cases may suffer further slow rate loss
of RGCs, as documented by a few cases studied post-mortem,
supporting a long-range neurodegenerative activity [1,3].
Most of the mutation carriers along the maternal line remain,
however, unaffected indicating that the mtDNA pathogenic
mutation is a necessary but not sufficient condition to develop
the optic neuropathy. Even in the absence of visual loss, the
unaffected mutation carriers may display subclinical changes at
fundus exam [6], neurophysiological and optical coherence
tomography investigations [7,8], as well as bioenergetic impair-
ment measured by biochemical testing and by in-vivo magnetic
resonance spectroscopy [9].
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e50230
LHON is, along with dominant optic atrophy (DOA), a non-
syndromic mitochondrial optic neuropathy, both being character-
ized by visual loss and optic nerve atrophy as the only or at least
prevalent pathological feature [1,2]. Optic nerve involvement may
also occur in more complex syndromes due to mitochondrial
dysfunction such as Friedreich’s ataxia (FRDA), in which diffusion-
weighted imaging (DWI) studies have demonstrated an involve-
ment not only of the optic nerve but also of the retro-geniculate
optic radiation (OR) [10,11]. Recently, two studies applying voxel-
based morphometry (VBM) and DTI approaches, pointed towards
OR abnormalities in LHON patients, suggesting trans-synaptic
degeneration without definitely excluding a primary dysfunction
[12,13]. This was suggested by previous phosphorus MR
spectroscopy (31P-MRS) investigations showing occipital lobes
bioenergetics dysfunction in LHON patients and unaffected
mutation carriers [9,14–16].
The aim of the present study was to better characterize the post-
geniculate involvement in LHON. We used DWI, a technique
demonstrated to disclose increased water diffusivity in the brain
areas where atrophy and/or gliosis occur [17], to investigate the
optic radiations in LHON patients and unaffected mutation
carriers. Furthermore, we studied the lateral geniculate nucleus
(LGN) in post-mortem specimens, comparing average neuron cell
body size and cell density between a LHON patient with severe
axonal loss in the optic nerve and an age-matched control.
Methods
Subjects
Twenty-two molecularly-certified LHON affected patients (17
males; age 33611, mean 6 SD), 11 unaffected mutation carriers
(5 males; age 45615) and 22 healthy controls (16 males; age
37617) were studied between February 2006 and December 2009
at the Functional MR Unit, University of Bologna, Italy. Exclusion
criteria were presence of neurological symptoms or signs not due
to the optic atrophy and evidence of grey/white matter alterations
on conventional MRI scanning. None of unaffected mutation
carriers and controls had a history of neurologic or psychiatric
diseases and conventional MRI scans appeared normal in all cases.
All participants gave their written informed consent and the study
was approved by the institutional review board of the Bologna
Hospital.
MR Examination
Subjects were studied in a 1.5 T General Electrics Medical
Systems (Milwaukee, Wisconsin) Signa Horizon LX whole-body
scanner. Structural imaging included T1- and T2-weighted fast
spin-echo scans. Axial DW images were obtained (slice thick-
ness = 5 mm, inter-slice gap= 1 mm) using a single-shot EPI
sequence (matrix size = 1926192). Orthogonal x, y and z
diffusion-encoding gradients were applied with gradient strengths
corresponding to b-values of 300, 600 and 900 s/mm2. In
addition, images without diffusion weighting were acquired,
corresponding to b= 0 s/mm2 and exhibiting T2-contrast. The
total DWI scan time was 2 min.
Distortions in the DW-EPI images due to gradient-induced
eddy currents were corrected using the image registration software
FLIRT (www.fmrib.ox.ac.uk/fsl). Due to the nature of the
distortions, the degrees of freedom were restricted to translation,
scaling, and shearing along the phase encoding direction [18].
Possible head movements were corrected using image registration
of each volume to the first restricting degrees of freedom to
translation and rotation. Mean diffusivity (MD) was determined
pixel-wise using a least-squares fit using the program DTIFIT. In
order to avoid contamination of the MD values for grey and white
matter by the much higher values of cerebral spinal fluid (CSF)
during further evaluation, pixels containing CSF were masked
from the MD map. This was accomplished using the FAST
algorithm for a two-class segmentation based on the corresponding
T2-weighted EPI images. Regions of interest (ROIs) (Fig. 1A–B)
were determined by segmentation of the left and right ORs on
three slices using the T2-weighted EPI images and were super-
imposed on the MD maps to obtain mean MD values. We also
delineated ROIs at the level of the prefrontal and cerebellar white
matter, as internal controls.
Pathological Examination
The postmortem lateral geniculate nuclei (LGN) from a pre-
viously studied 75 year-old female LHON patient [3] and a 75
year old female control individual were analysed at the Doheny
Eye Institute, Los Angeles, California. The control brain was
acquired from the Alzheimer’s Disease Research Center at the
University of Southern California, having no evidence of either
Alzheimer’s Disease or other neurodegenerative diseases at the
pathological report. The LHON patient had an extremely severe
chronic optic neuropathy and carried the homoplasmic 3460G.A
mutation. The LGNs for both cases were taken from fixed brains
in neutral buffered formalin, dissected in a coronal plane,
processed for and embedded into paraffin blocks, sectioned, and
placed on glass microscope slides. The tissue sections were stained
with hematoxylin for Nissl substance to allow for identification of
the cell bodies and coverslipped using permanent mounting
media.
Image acquisition was performed using the T3 Aperio C3
digital scanning microscope (Aperio Corporation, Vista, CA) with
the ImageScope analysis software package. The two LGN slides
were digitized by the microscope using a 40x objective, which
provides a 0.25 mm per pixel scanning resolution [19]. In each
digitized LGN the two magnocellular and four parvocellular layers
were identified (Figure 2 bottom panel). The six layers were
each further subdivided into nasal, middle, and temporal zones for
analysis purposes providing a total of 18 separate areas. The
average cell size was then calculated using a custom algorithm
built in the ImageScope software package designed to detect all
areas that stained blue with hematoxylin. Only areas of positive
staining that were greater than 100 mm2 were counted, as smaller
areas likely represented intergeniculate or glial cell bodies and not
neuronal cell bodies-. Following the software analysis, each section
was further examined by the same observer for confirmation. Cell
bodies that were not counted or counted in error by the software
were manually corrected.
Postmortem optic nerves were fixed in a mixture of buffered
glutaraldehyde/paraformaldehyde, dissected into cross-sections
from both the LHON patient and the control subject. The tissues
were then processed for and embedded into plastic, sectioned, and
stained with p-Phenylenediamine (PPD) (Figure 2, top panel).
Myelinated axonal profiles were counted as previously detailed
[3,20].
Statistical Analysis
Statistical analyses were performed using SPSS 14.0 for
Windows. Parametric tests were used as Kolmogorov–Smirnov
testing showed that the variables were normally distributed. One-
way analysis of variance (ANOVA) followed by a post-hoc LSD
test was used for comparison between groups. P values less than
0.05 after Bonferroni correction for multiple comparisons were
accepted as statistically significant. To investigate the effect of
genetic, demographic and clinical parameters (gender, type of
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mutation, age at onset, disease duration, and history of recovery of
visual acuity) on DWI data, we used a general linear model (GLM)
in which mean optic radiation diffusivity was the dependent
variable, the categorical variables were defined as random factors
and continuous variables as covariates, without interactions. For
pathological examination we performed a descriptive analysis.
Results
Clinical and Genetic Features
All patients had the typical clinical and ophthalmological
features of LHON. Fourteen had the G11778A/ND4, seven the
G3460A/ND1, and one the T14484C/ND6 homoplasmic muta-
tions. Six patients (two with 11778/ND4, three with 3460/ND1
and one with 14484/ND6 mutation) had a history of bilateral
recovery of visual acuity (current visual acuity ranged from 0.125
to 1) whereas the remaining cases did not (current visual acuity
ranged from 0.0025 to 0.075). Patients were considered to have
recovered visual acuity after a gain of at least two lines on Snellen
acuity or a change from ‘‘off chart’’ to ‘‘on chart’’, as previously
established [21,22]. All patients were administered with idebenone
as previously reported [5]. Age at onset ranged from 2 to 44 years
(mean=20 years), and disease duration from 1 to 35 years
(mean=14 years). Unaffected LHON mutation carriers (eight
with the 11778/ND4 and three with the 3460/ND1 mutation) did
not present any visual or neurological symptoms and had normal
visual acuity.
MR Findings
Conventional MRI did not demonstrate abnormalities in both
the LHON patients and carriers.
In DWI analysis right- and left-side MD values were not
statistically different for all ROIs and are reported as mean. One-
way ANOVA detected a group difference (F= 6.8; P,0.01) only
in ORs and post hoc testing revealed an increase in OR MD of
LHON patients compared with both unaffected LHON mutation
carriers (P,0.05) and healthy subjects (P,0.01) (Fig. 1C). Optic
radiation MD values were similar in unaffected mutation carriers
and healthy subjects. In LHON patients GLM analysis disclosed
that lack of visual acuity recovery (B = 0.060; P,0.01) and disease
duration (B= 0.002; P,0.05) were significantly associated with
increased OR MD values (Table 1).
Pathological Findings
Pathologic examination of the LGNs from the LHON patient
showed a marked decrease in the average neuron soma across all
six layers (Figure 2, bottom panel; Figure 3). The average
neuron soma size in the magnocellular layers (layers 1 and 2) of the
LHON LGN was smaller than the control LGN (41.9% decrease).
Also, the average neuron soma size in parvocellular layers of the
LHON tissue was smaller than the average found in any layer of
the control LGN (44.7% decrease). However, because the relative
magnitude of the cell size decrease was similar across all six layers
of the LHON LGN, the ratio between the cell size of the
magnocellular and parvocellular layers was similar in both the
LHON (1.51) and control (1.44) LGNs (Table 2). No consistent
differences were noted in cell size between the nasal, middle
(corresponding to the papillomacular bundle), or temporal zones
or individual layers. Additionally, the average neuron density of
the LHON LGN was decreased across all layers (Table 2). The
two magnocellular layers of the LHON LGN had a reduced
average density by 28.5%, and the parvocellular layers of the
LHON LGN had a reduced average density by 28.7% when
compared with the control LGN.
The post-mortem retrobulbar optic nerve of the LHON patient
stained with PPD showed a dramatic reduction in axonal profiles,
which were counted as 8,200 in the left eye (over 99% decrease) as
compared to the 993,762 axons counted in the age-matched
control (Figure 2, top panel). The counts of this age-matched
control were consistent with previously reported axonal counts of
normal individuals in their 70s [23].
Figure 1. Segmentation of ROIs including prefrontal white matter (A), cerebellar white matter (B) and optic radiation (C) on axial T2
images. D: 3D reconstruction of optic radiation ROIs on a registered T1 volumetric image. E: Box-plot of MD values of optic radiations in controls,
LHON healthy carriers and LHON patients. (Each box shows the median, quartiles, extreme values; * = P,0.01).
doi:10.1371/journal.pone.0050230.g001
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Discussion
In this study we have demonstrated increased diffusivity in the
optic radiations (OR) of patients with LHON using diffusion-
weighted imaging (DWI). No differences were detected for
diffusivity values in the prefrontal and cerebellar white matter.
These results confirm the previous observation of post-geniculate
abnormalities in LHON patients [12,13]. DWI changes in OR of
LHON affected patients were more severe in those who failed to
recover visual acuity and had longer disease duration, whereas
they were not detected in unaffected LHON mutation carriers.
Furthermore, pathological analysis of the LGN showed three
important findings: i) LHON LGN atrophy as evidenced by the
significant decrease in the average neuron cell size; ii) LHON
LGN degeneration shown by a decrease in neuron density; iii) the
changes were consistent across all layers of the LGN as the percent
decrease in density was the same for both magnocellular and
parvocellular layers, with a similar ratio between the magnocel-
lular and parvocellular layers either in the LHON as in control
LGNs.
A previous diffusion-weighted study in LHON found no post-
geniculate changes, but this was probably related to the small
sample size (ten patients) and the smaller ROI size used [24].
Conversely, another magnetisation transfer (MT) imaging and
DWI study from the same group [25] reported significantly lower
MT ratio histogram peak height and a trend towards significant
increase of average diffusivity values in LHON patients, using
histogram analysis of the whole normal appearing white matter,
a technical approach with greater statistical power [11]. The
authors interpreted these findings as a reflection of the tissue loss
and disorganization in the visual pathway or of diffuse and
microscopic brain pathology. Both hypotheses might explain the
small change in the histograms. Our data corroborate the first
hypothesis disclosing changes only in the ORs and not in the
extra-visual white matter. Furthermore, two more recent imaging
studies documented the specific post-geniculate involvement in
LHON patients [12–13]. A VBM study demonstrated significant
reduced grey matter volume in the bilateral primary visual cortex,
and reduced white matter volume in several areas located in the
optic radiations, bilaterally [12]. The same group, using diffusion
tensor imaging, reported significant diffusivity abnormalities at
level of the OR of LHON patients [13]. These studies, unlike the
present study, failed to disclose a correlation with disease duration,
probably due in part to their inferior statistical power (considering
Figure 2. Top panel: optic nerves in cross-section and stained by p-Phenylenediamine for control and LHON patient (25x
magnification). In the LHON patient only a small patch of fibers remains (arrow) in the super-nasal quadrant. Bottom panel: lateral geniculate nuclei
(LGN) of control and LHON patients with all magnocellular (1 and 2) and parvocellular (3–6) layers identified (25x magnification). Insets represent
samples of each zone at 200x magnification.
doi:10.1371/journal.pone.0050230.g002
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12 [12] and 13 [13] patients respectively, compared to the 22 of
the present study) and the different statistical analysis employed
(single correlations [12–13] vs the GLM model in our study).
These studies did not clarify whether post-geniculate damage in
LHON is due to trans-synaptic degeneration or mitochondrial
dysfunction. Indeed, previous 31P MRS studies detected metabolic
abnormalities in the occipital white matter lobes from both LHON
patients and healthy carriers [9,14–16]. These observations may
suggest that the structural changes in OR were primary and
related to degenerative changes due to the mitochondrial
dysfunction. On the other hand, our results showed an absence
of DWI alterations in LHON carriers and an increase of MD
values more evident in LHON patients with longer disease
duration and lack of recovery of visual acuity, who are known to
have fewer optic nerve fibers compared with LHON patients who
recovered [22]. Moreover, extra-visual LHON white matter was
not affected. These observations suggest that in LHON patients,
involvement of the posterior visual pathways is secondary to trans-
synaptic atrophy or degeneration.
Table 1.MD values of optic radiation, prefrontal white matter and cerebellar white matter in LHON patients, LHON healthy carriers
and controls with group comparison results (first two sections).
One-way ANOVA
ROI*
LHON patients MD
(61023 mm2/s)
LHON carriers MD
(61023 mm2/s)
Controls MD
(61023 mm2/s) P#
Optic radiation 0.8660.04 0.8260.04 0.8260.03 ,0.01
Prefrontal WM 0.7560.04 0.7560.02 0.7760.04 n.s.
Cerebellar WM 0.7360.04 0.7360.05 0.7460.05 n.s.
Post-hoc LSD test for optic radiation MD values
LHON patients vs healthy controls ,0.01
LHON patients vs unaffected LHON carriers ,0.05
unaffected LHON carriers vs healthy controls n.s.
GLM (dependent variable: optic radiation MD values in LHON patients)
Disease duration B= 0.002; P =,0.05
Lack of recovery of visual acuity B= 0.06; P =,0.01
The bottom of the table shows the results of GLM analysis used to evaluate the effect of genetic, clinical and demographic data on optic radiation MD values in LHON
patients.
* =mean of left and right MD values.
#= corrected for multiple comparisons.
Values are reported as mean and standard deviation.
MD: mean diffusivity; WM: white matter; n.s.: not significant; GLM: general linear model.
doi:10.1371/journal.pone.0050230.t001
Figure 3. Average neuron soma size of all layers in the LGNs from the LHON patient and the age-matched control.
doi:10.1371/journal.pone.0050230.g003
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Trans-neuronal or trans-synaptic degeneration consists of
atrophy or degeneration of post-synaptic neurons deprived of
their afferents and has been described in a variety of neural
systems [26]. In the visual system, such evidence of dysfunction of
the posterior visual pathways, i.e. LGN, OR and calcarine cortex,
has been reported as secondary to loss of retina and/or optic nerve
after enucleation of one eye [27], chronic glaucoma [28,29],
retinal degeneration [30], and optic neuritis [31]. Concerning
optic neuritis and multiple sclerosis, the relevance of trans-synaptic
degeneration is currently debated, with particular reference to the
grey matter involvement [31,32,33]. At the LGN level trans-
synaptic changes have been described as neuronal atrophy (cell
shrinkage) and, in long-lasting conditions as advanced glaucoma,
as neuronal loss [28,29]. This matches well with our pathological
findings in the LGN of a LHON patient with very long disease
duration (53 years) and a particularly severe loss of vision (light
perception), consistent with axonal loss of over 99% in the optic
nerve. We documented mostly neuronal atrophy and, to a lesser
extent, some neuronal loss. These changes were consistent across
both magno-cellular and parvo-cellular layers of the LGN well
fitting the data from trans-neuronal degeneration studies in
glaucoma, reporting a different cell loss between magno-cellular
and parvo-cellular layers when the RGC axon loss is mild and an
equivalent cell loss in all layers when the RGC axon loss is near to
100% (28), as in our LHON patient. Similar results were described
for the LGN in old, pre-molecular, post-mortem histopathological
studies in a few patients affected by optic atrophy compatible with
the LHON diagnosis [34–36]. Accordingly, the in vivo abnormal-
ities of OR observed by DWI in LHON patients with a shorter
disease duration probably reflected neuronal cell and axonal
atrophy (shrinkage) secondary to a reduction of synaptic inputs.
This suggests that if action potentials could be re-established in the
spared axons of the optic nerve, as possibly occurs in those patients
recovering visual acuity after the acute phase [1,2,4,5], the
recovery of the synaptic inputs might lead to recovery of atrophic
but still viable neurons in the LGN and their axons in the optic
radiations. Thus, it is possible that the neuron soma shrinkage
represents a fairly long therapeutic window of opportunity prior to
cell death. The further development of post-geniculate changes
with increasing RGC and axonal loss suggests that any effective
treatment should be early. Nevertheless, treatment could be useful
even in the later stages of the disease, as suggested by the slow
recovery of visual acuity, spontaneous or after idebenone
treatment in LHON [1,2,4,5]. Unfortunately, we could not study
a further group of LHON patients without idebenone therapy in
order to investigate its possible influence on DWI parameters.
However, it should be noted that idebenone has been shown to
increase recovery rate in LHON patients (5), and in our opinion,
recovery of visual acuity was the most powerful variable potentially
impacting on post-geniculate integrity. Future work should directly
investigate this important issue.
A limitation of this study is the use of DWI rather than DTI
(diffusion tensor imaging), not available at our institution when the
study was started, that precluded the measurement of other
parameters such as fractional anisotropy, parallel diffusion, and
radial diffusion, which might have given more information about
the type of degeneration occurring in the long white matter tracts
[37]. Interestingly, the previous DTI study detected decreased
fractional anisotropy and an increased radial diffusivity in the OR
of LHON patients [13], consistent with the DTI changes observed
in the chronic stages of secondary axonal degeneration [38]. At
most the use of DWI should have reduced the sensitivity of the
analyses, creating a bias towards negative results. The limitation of
our use of DWI is partially mitigated by the integration with the
pathological analysis of LGN that provided an independent
confirmation on the changes detected. The latter, despite being
performed in a single case showed histopathological changes that
were very similar to other descriptions of LGN histopathology
performed in LHON patients prior to the availability of molecular
diagnosis [34–36].
A further relative limitation of our study is the lack of retinal
nerve fiber layer (RNFL) data from optical coherence tomography
investigations (OCT) for use in the correlation analysis, as not all
our patients had undergone OCT while others with available
OCT had undergone the examination too far from the MR
acquisition. The finding of a correlation between RNFL data and
OR changes would further support the transneuronal hypothesis.
Notably, such a correlation was found in the previously cited VBM
study [12]. In conclusion, this study extends the results of recent
similar investigations, by using a larger group of well-characterized
LHON patients and adding the rare opportunity to verify on
a single post-mortem specimen the MR finding at the histological
level. Using DWI, we detected microstructural changes in ORs
and not in extra-visual white matter of LHON affected patients.
This was more evident in LHON patients with longer disease
duration and absence of recovery of visual acuity. In contrast, the
unaffected LHON carriers showed no changes despite previous
evidence of metabolic impairment in the same pathway. Patho-
logical examination of the LGN from the single separate LHON
patient with very severe optic atrophy suggested that these
microstructural changes were mainly due to neuronal and axonal
atrophy of the post-synaptic cell. Thus, the post-geniculate
involvement in LHON patients is most likely a downstream
secondary phenomenon, from chronic de-afferentation, rather
than mitochondrial dysfunction associated with primary neurode-
generation.
Table 2. Top: neuron soma size by layer type for LHON and
control LGN.
Lateral geniculate nucleus: cell body size by layer type
Layers Control LHON % decrease
1–2 (magnocellular) 388.54 mm2 225.68 mm2 41.92%
3–6 (parvocellular) 269.77 mm2 149.22 mm2 44.69%
Ratio 1.44 1.51 /
Lateral geniculate nucleus: cell density by layer type
Layers Control LHON % decrease
1–2 (magnocellular) 185.74 cells/
mm2
132.76 cells/
mm2
28.52%
3–6 (parvocellular) 263.46 cells/
mm2
187.80 cells/
mm2
28.72%
Optic nerve: axonal counts
Control LHON % decrease
993,762 8,200 99.17%
The ratio of the magnocellular to parvocellular layers for the two LGN is similar
suggesting that the atrophy seen in the LHON case was consistent across all
layers. Middle: average cell density of the magnocellular and parvocellular
layers for both the LHON and control LGNs. LHON LGN exhibits a decrease in
neuron density consistent across both cell layer types. Bottom: axonal counts
for LHON and control left optic nerve.
doi:10.1371/journal.pone.0050230.t002
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